CytoMed Therapeutics Ltd
GDTC · Pharmaceutical Preparations · EDGAR filings ↗
Reference price $1.15 — last insider purchase, 2026-05-13 (estimated from the dated SEC Form 4 price — not a live quote)
Grade
D44Early clinical-stage cell-therapy company with going-concern doubt and under two quarters of cash.
Strengths
- Low leverage (D/E 0.06) and adequate current ratio 5.2x
- Revenue growth 90th pct (small base) with grant/co-funding support
Risks
- Going concern doubt; cash S$2.1M, ~1.9-quarter runway (15th pct)
- Early pipeline, no approved products, deep losses (net margin -1232%)
- Reliant on dilutive ATM and future financing
Notable findings
- Going concernIf we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources
- Net lossNet loss (net margin -1232.0%)
- Cash burnNegative free cash flow (-3.4M)
- Insider buyingInsider buying — 1 open-market buy(s) by 1 insider(s) (~$128,778, last 6mo) Form 4 ↗
Key metrics
Net margin
-1232.0%
Return on equity
-58.3%
Return on assets
-50.0%
Revenue growth (QoQ)
394.7%
Debt / equity
0.1×
Current ratio
5.2×
Free cash flow
-$3M
Tangible book value
$5M
Cash & investments
$2M
Cash runway
2q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-13 | Choo Chee Kong | Buy | 112K | $1.15 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT05302037 ↗ | Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA) Cancer, Malignancy | PHASE1 | Recruiting | 2025-11-01 |
| NCT04107142 ↗ | Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour Colorectal Cancer, Triple Negative Breast Cancer | PHASE1 | Unknown | 2020-09-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-03-31 | 2025-12-31 | 0001493152-26-013813 ↗ |
| 20-F | 2025-04-28 | 2024-12-31 | 0001641172-25-006458 ↗ |
| 20-F | 2024-04-22 | 2023-12-31 | 0001493152-24-015594 ↗ |
| 20-F | 2023-05-01 | 2022-12-31 | 0001493152-23-015042 ↗ |